Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer

The androgen receptor (AR) is widely expressed in breast cancer (BC) and evidence suggests dependence on AR signaling for growth and survival. AR antagonists such as enzalutamide and seviteronel have shown success in pre-clinical models and clinical trials of prostate cancer, and are currently being...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Cancer Ther
Asıl Yazarlar: Gordon, Michael A., D'Amato, Nicholas C., Gu, Haihua, Babbs, Beatrice, Wulfkuhle, Julia, Petricoin, Emanuel F., Gallagher, Isela, Dong, Ting, Torkko, Kathleen, Liu, Bolin, Elias, Anthony, Richer, Jennifer K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5517319/
https://ncbi.nlm.nih.gov/pubmed/28468774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0111
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller